While the maintenance of a Buy rating suggests continued confidence in Lyell Immunopharma's potential, the reduction in the price target could reflect adjustments in valuation metrics or expectations for the company's future performance. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market digests the implications.